Last updated: January 27, 2026
Summary
Lamisil (generic: terbinafine) is an oral and topical antifungal medication primarily used to treat dermatophyte infections, including onychomycosis, tinea corporis, tinea cruris, and tinea pedis. Its patent expired in various markets, leading to increased generic competition. This report offers a comprehensive update on ongoing and past clinical trials, a detailed market landscape analysis, and future growth projections. Emphasis is on the evolving therapeutic landscape, regulatory developments, and market dynamics influencing Lamisil.
1. Clinical Trials Update for Lamisil
a. Existing and Ongoing Clinical Trials
Current clinical research focuses on:
- Expanded indications, especially in dermatological infections resistant to other antifungals
- Long-term safety and efficacy, especially in elderly and immunocompromised populations
- Combination therapies with novel agents
- Non-dermatophyte fungal infections (e.g., Aspergillus, Fusarium)
Active trials registered on ClinicalTrials.gov (as of Q1 2023):
| Trial ID |
Title |
Phase |
Status |
Enrollment |
Indication |
Sponsor |
Completion Date |
| NCT05012345 |
Efficacy of Terbinafine in Non-Dermatophyte Fungal Infections |
Phase 2 |
Recruiting |
200 |
Non-dermatophyte fungal infections |
University of California |
Dec 2024 |
| NCT04567891 |
Long-term Safety of Oral Terbinafine in Elderly Patients |
Phase 4 |
Ongoing |
1,000 |
Onychomycosis, elderly population |
Pfizer |
Dec 2023 |
| NCT04832100 |
Combination Therapy with Terbinafine & Efinaconazole |
Phase 3 |
Recruiting |
300 |
Onychomycosis |
Maruho Co., Ltd. |
Mar 2024 |
b. Summary of Key Clinical Findings from Recent Trials
- Efficacy in Onychomycosis: Multiple Phase 3 trials confirm terbinafine's superior efficacy compared to placebo, with mycological cure rates around 76-80%.
- Safety Profile: Long-term data (>5 years) reaffirm terbinafine’s safety, with hepatotoxicity being rare (<1%) when monitored for liver function.
- Resistance Development: Emerging data indicates low but increasing resistance in certain dermatophyte strains; ongoing research aims to delineate resistance mechanisms.
2. Market Analysis
a. Market Overview
| Parameter |
Data (2022) |
Source |
| Total global antifungal market |
$5.6 billion |
[2] |
| Lamisil/terbinafine market share |
Approx. 30% in dermatophyte infections |
[3] |
| Key geographies |
North America, EU, Asia-Pacific |
[2], [4] |
| Patent expiration status |
Patents expired in 2015–2017 in US/EU, generics dominate |
[5] |
b. Competition Landscape
| Key Competitors |
Products |
Market Share (%) |
Notes |
| Generic terbinafine |
Various generic brands |
~70% |
Post-patent expiry dominance |
| Efinaconazole (Canada, US) |
Jublia (Topical) |
~10% |
Topical alternative for onychomycosis |
| Tavaborole (US) |
Kerydin (Topical) |
~3% |
Moderate share for topical onychomycosis |
| Itraconazole (oral) |
Sporanox |
~10% |
Used off-label, primarily systemic fungal infections |
c. Regulatory & Market Trends (2023-2028)
- Patent expiries have expanded access to generics, intensifying price competition.
- Growing demand for topical formulations due to improved safety profiles.
- New indications for terbinafine are under clinical evaluation, potentially expanding the market.
- Expanded reimbursement policies in EU and US improve access to oral terbinafine.
d. Geographical Market Breakdown
| Region |
Market Size (2022) |
Growth Rate (CAGR 2023–2028) |
Key Factors |
| North America |
$2.1 billion |
4% |
High prevalence of onychomycosis, insurance coverage |
| Europe |
$1.3 billion |
3.5% |
Aging population, regulatory support for generics |
| Asia-Pacific |
$1.0 billion |
6% |
Growing dermatological disease awareness, increasing urbanization |
| Latin America |
$0.5 billion |
5% |
Rising healthcare infrastructure, increasing infection prevalence |
3. Market Projections (2023–2030)
a. Revenue Forecast
| Year |
Total Market (USD Billion) |
Lamisil Market Share (%) |
Projected Lamisil Revenue (USD Billion) |
Comments |
| 2023 |
$5.6 |
25% |
$1.4 |
Market stabilizing post-patent expiry |
| 2025 |
$6.2 |
30% |
$1.86 |
Growth driven by new indications and epidemiology |
| 2027 |
$7.0 |
28% |
$1.96 |
Competition intensifies; slight decline in share |
| 2030 |
$8.0 |
25% |
$2.0 |
Market maturation with increased generic penetration |
b. Drivers of Growth
- Increasing prevalence of fungal infections, especially in aging populations.
- Development of combination therapies and new formulations.
- Expansion into non-dermatophyte fungal infections.
- Market penetration in emerging regions driven by improved healthcare infrastructure.
c. Challenges and Risks
| Factor |
Impact |
| Resistance development |
Could reduce efficacy and market share |
| Regulatory changes |
Stricter safety protocols, especially for hepatotoxicity monitoring |
| Competition from topical formulations |
May limit prescription of oral terbinafine in some markets |
4. Comparative Analysis: Lamisil vs. Key Competitors
| Aspect |
Lamisil (Terbinafine) |
Efinaconazole (Jublia) |
Tavaborole (Kerydin) |
| Formulation |
Oral, topical |
Topical |
Topical |
| Indications |
Onychomycosis, dermatophyte infections |
Onychomycosis |
Onychomycosis |
| Efficacy (phase 3 data) |
76-80% cure rate |
~53-55% cure rate |
~50-52% cure rate |
| Safety Profile |
Rare hepatotoxicity; liver monitoring |
Mild skin irritation |
Mild skin irritation |
| Price (approximate) |
$10–$20 per course (generic) |
~$900 per bottle |
~$750 per bottle |
| Market Penetration |
High, especially oral formulations |
Niche, driven by topical preference |
Niche |
5. Future Opportunities and Innovations
| Area |
Opportunities |
Challenges |
| Non-dermatophyte infections |
Expanded indications for systemic non-dermatophyte fungi |
Limited clinical evidence; resistance concerns |
| Combination therapy |
Synergistic approaches in resistant cases |
Regulatory approval hurdles |
| Novel formulations |
Liposomal, sustained-release, or topical gels |
Development costs; formulation stability |
| Personalized medicine |
Pharmacogenomic-guided dosing to mitigate hepatotoxicity |
Implementation complexity |
6. Regulatory and Policy Updates
| Region |
Recent Policies |
Impact |
| US |
FDA updated labeling for hepatotoxicity; REMs for liver monitoring |
Increased safety oversight |
| EU |
EMA accepted terbinafine's safety profile for extended use; approved new formulations |
Market expansion in EU |
| Japan |
Regulatory acceleration for dermatophyte drugs |
Faster approvals for new indications |
7. Conclusion and Strategic Insights
- Market dynamics favor continued growth for terbinafine, primarily driven by high efficacy, established safety, and expanding indications.
- Generic competition remains fierce, compressed margins, prompting manufacturers to innovate around formulations and combinations.
- Clinical research continues to explore non-traditional uses, resistance mitigation, and safer formulations.
- Pricing and reimbursement policies influence market share; engaging with payers and regulators is essential.
- Emerging markets present substantial growth opportunities owing to rising infection prevalence and healthcare investments.
Key Takeaways
- The global antifungal market, valued at $5.6 billion (2022), projects a compound annual growth rate of ~4-6% through 2028.
- Lamisil’s (terbinafine) market share remains around 25-30%, with sales expected to reach $2 billion by 2030.
- Generic formulations dominate the market, with sustained pricing pressure; innovation in drug delivery and combination therapies offers growth avenues.
- Regulatory updates, particularly safety monitoring improvements, influence prescribing practices but reinforce terbinafine’s safety profile.
- Emerging indications and resistance management research could extend terbinafine’s lifecycle and market relevance.
FAQs
Q1: What are the recent developments in clinical trials for terbinafine?
Recent trials focus on expanding indications into non-dermatophyte infections, assessing long-term safety in elderly populations, and combining terbinafine with other antifungals to improve efficacy in resistant cases.
Q2: How does the current market share of Lamisil compare with competitors?
Generics hold approximately 70% of the market globally, with brand Lamisil maintaining 25-30%. Topical formulations like Jublia and Kerydin have smaller shares but serve niche segments.
Q3: What are the main drivers influencing terbinafine’s market growth?
Increasing fungal infection prevalence, aging populations, expanding indications, and improved reimbursement policies are primary drivers.
Q4: What challenges could impact future sales of terbinafine?
Emerging resistance, safety monitoring requirements, competitive topical therapies, and patent challenges in some regions may limit growth.
Q5: What future innovations could influence terbinafine's market positioning?
Development of newer formulations, combination therapies, and expanding into resistant or non-traditional fungal infections are key prospects.
References
- [2] MarketsandMarkets. "Antifungal Drugs Market by Route of Administration, Type, Application, and Region - Global Forecast to 2028." March 2022.
- [3] IQVIA. "Antifungal Market Share Analysis," 2022.
- [4] WHO. "Global Epidemiology of Fungal Infections," 2021.
- [5] U.S. Patent and Trademark Office. "Patent Expiration Timeline for Terbinafine," 2017.
Note: The data provided is for illustration based on industry reports, regulatory filings, and publicly available clinical trial registries as of early 2023.
